A Randomized Phase II Trial on the Addition of Dutasteride to Combined Androgen Blockade Therapy Versus Combined Androgen Blockade Therapy Alone in Patients with Advanced or Metastatic Salivary Duct Carcinoma – The DUCT Study Protocol

    September 2024 in “ BMC Cancer ”
    Jetty A.M. Weijers, Gerald W. Verhaegh, Gerben Lassche … Carla M.L. van Herpen
    Studysummary In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Key Targets of Hormonal Treatment of Prostate Cancer: The Androgen Receptor and 5α-Reductase BJU international · 2009

    Related research 4

    1. Evaluation of the Therapeutic Effects of AGA Drugs by Measuring Finasteride, Dutasteride, and Dihydrotestosterone in Hair Clinica Chimica Acta · 2023
    2. Luncheon Symposium: Update on the Efficacy and Safety of Dutasteride in the Management of Androgenetic Alopecia 프로그램북(구 초록집) · 2015
    3. The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride Journal of The American Academy of Dermatology · 2006
    4. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor ˜The œJournal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism · 2004